Placebo control

Phase 3

Haisco Pharmaceutical Group Co., Ltd.

Placebo control is one of 66 therapeutic programs targeting Chronic Spontaneous Urticaria. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Chronic Spontaneous UrticariaCompleted

OsteoarthritisCompleted

COPD (chronic Obstructive Pulmonary Disease)Not yet recruiting

Chronic Spontaneous UrticariaPhase 2

Completed

OsteoarthritisPhase 3

Completed

COPD (chronic Obstructive Pulmonary Disease)Phase 3

Not yet recruiting

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Placebo control

Haisco Pharmaceutical Group Co., Ltd.

Phase 3

1 2

Epidiolex

Jazz Pharmaceuticals

Preclinical

4 3

Voltaren

CCerimon Pharmaceuticals

Preclinical

4 4

Glucophage

Boehringer Ingelheim

Preclinical

1 5

Chirocaine

PPurdue Pharma LP

Preclinical

1 6

Lunesta

Akero Therapeutics

Preclinical

1 7

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 8

Catapres

Boehringer Ingelheim

Preclinical

1 9

Benadryl

PParkedale

Preclinical

—10

Western Medicine

PPeking Union Medical College Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Not yet recruiting

COPD (chronic Obstructive Pulmonary Disease)

NCT07658339

Clinical

Trials by Indication[1]

Osteoarthritis1 trial

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 3 Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 Osteoarthritis of the Knee

Completed·KKolon TissueGene, Inc.·Phase 3·NCT03291470·531 enrolled

Chronic Spontaneous Urticaria1 trial

A Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria

Completed·EEvommune, Inc.·Phase 2·NCT06873516·182 enrolled

COPD (Chronic Obstructive Pulmonary Disease)1 trial

A Phase III Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Study to Evaluate the Efficacy and Safety of HSK39004 Inhalation Suspension in the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

Not yet recruiting· Haisco Pharmaceutical Group Co., Ltd. logo

Haisco Pharmaceutical Group Co., Ltd.·Phase 3·NCT07658339·387 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Placebo control. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Placebo control. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Haisco Pharmaceutical Group Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Haisco Pharmaceutical Group Co., Ltd.

Placebo control

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Osteoarthritis1 trial

Chronic Spontaneous Urticaria1 trial

COPD (Chronic Obstructive Pulmonary Disease)1 trial

References

Drug Info

Quick Facts

Related News